All lectures will be available to watch on demand from: October 22nd 2021, at 8:00 AM CET TIME

Dr Charles Swanton 10:00 am CEST

​The Francis Crick Institute - Cancer Research UK - University College London Cancer Institute, UK

Tumor evolution through Liquid Biopsy

Dr Catherine Alix-Panabieres 10:00 am CEST

The Laboratory 'Cellules Circulantes Rares Humaines ' (LCCRH) University Medical Center of Montpellier in France (University of Montpellier - UM), France

Role of Circulating Tumor Cells in Metastatic Cascade

Dr Juan Manuel Falcón

Ikerbasque Research Professor at CIC bioGUNE, Derio, Bizkaia, Spain

Use of metabolomics to understand treatment resistance

Dr Sabine Kasimir-Bauer

Associate Professor, University of Duisburg Essen, Germany

Phenotypic and functional analyses of CTC : Sab

Dr Nicola Aceto

Swiss Federal Institute of Technology (ETH) Zurich, Switzerland

Biology and vulnerabilities of CTC clusters

Dr Qiang Zang

Robert H Lurie Comprehensive Cancer Center, Northwestern University,

Chicago, Illinois, USA

Culture of Circulating Tumor Cells reality and xenograft

Dr Héctor Peinado

Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Metastatic niche and Extracellular Vesicles

Dr Kenneth O'Byrne

Princess Alexandra Hospital, Translational Research Institute and Queensland University of Technology, Brisbane, Australia

Novel diagnostic exosomal protein and genomic biomarkers in cancer

Stephanie Jordaens PhD

Biomedical Scientist, NOVOSANIS, Belgium

Urine as the golden sample for cancer biomarker detection

CONS ► Dr Lynette M. Sholl

Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA

PROS ► Dr Philip Mack

University of California Davis Comprehensive Cancer Center, Sacramento, CA - Mount Sinai Tisch Cancer Institute, New York, NY, USA

Dr Miguel Angel Molina-Vila

Pangaea Oncology, Quirón Dexeus University Hospital, Barcelona, Spain

RNA analysis liquid biopsies of cancer patients: from fusion detection to gene signatures

Dr Christian Rolfo

Mount Sinai Medical System & Icahn School of Medicine, Mount Sinai, New York, NY, USA

ISLB President - Congress welcome and introduction

Dr Federica Di Nicolantonio

Laboratory Molecular Oncology at the Candiolo Cancer Institute IRCCS - Candiolo (Torino), Italy

Molecular mechanisms of cell free DNA release by colorectal cancer

Dr Umberto Malapelle

Department of Public Health, University of Naples Federico II, Naples, Italy

Molecular mechanisms of cell free DNA release in solid tumors

Dr Natasha Leighl

Medical Oncology, Princess Margaret, Toronto, ON, Canada

How to balance Next Generation Tumor Tissue testing versus Liquid Biopsy algorithms in the clinic

Dr Charu Aggarwal

Dept of Medicine, Division of Hem/Onc, University of Pennsylvania, PA, USA

Identifying mechanisms of Acquired Resistance in Oncogene-driven Cancers

Dr Maria E. Arcila

Memorial Sloan-Kettering Cancer Center, New York, NY, USA

Liquid Biopsy: Institutional testing platforms versus Central Laboratory

Dr Sarah-Jane Dawson

University of Melbourne, Australia

Liquid biopsy for targeting treatment resistance in Breast Cancer: A moving target

Dr Heinz Josef Lenz

University of South California USC, USA

Molecular Landscape in Colorectal Cancer: Opportunities for Liquid Biopsy

Dr Chiara Cremolini

University of Pisa, Azienda Ospedaliero-Universitaria Pisana, at the Tuscan Tumor Institute in Pisa, Toscana, Italy

ctDNA for treatment selection and treatment resistance in colon cancer

Dr Sergio Marchini

IRCCS, Humanitas Research Hospital, Milan, Italy

Clinical application of liquid biopsies to detect somatic BRCA1/2mutation in ovarian cancer

Dr Johann De Bono

The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, UK

Clinical Utility of Liquid Biopsy in Advanced Prostate Cancer

Dr David Gandara

Department of Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento, California, USA

Liquid Biopsy in the clinical management of NSCLC patients

Dr Lillian Siu

Princess Margaret, Ontario, Canada

Circulating Biomarkers for Immunotherapy: How to integrate in clinical trials

Dr Pier Vitale Nuzzo

Dana Farber Cancer Institute, Boston, MA, USA

Epigenetic and Liquid Biopsy

Dr Alberto Bardelli

Candiolo Cancer Institute IRCCS - Candiolo (Torino), Italy

Liquid biopsy driven, interventional clinical trials in CRC

Dr Toni Choueiri

Dana Farber Cancer Institute, Boston, MA, USA

Integrating ctDNA and tissue genomic profiling in renal cancer

Dr Eloísa Jantus Lewintre

Universitat Politècnica de València, Spain

Characterization of circulating TCR repertoire.
Role as biomarker for immunotherapy in NSCLC

Dr Luis Raez

Memorial Healthcare System, Pembroke Pines, USA

Monitoring Clinical Outcomes with Liquid biopsies (cfDNA and cfRNA) 

Dr Nicole Kruderer

Advanced Cancer Research Group, Kirkland, Washington

Comparative effectiveness of ctDNA in Breast Cancer 

Dr Leomar Y Ballester

University of Texas Health Science at Houston, USA

Analyzing Circulating Tumor DNA in the Cerebrospinal Fluid of Cancer Patients

Dr Andrés Cardona

Research director en "Luis Carlos Sarmiento Angulo" Cancer Treatment and Research Center (CTIC), Colombia

Pan-methylation analysis in liquid biopsy: a novel perspective

Dr Max Diehn

Stanford University, Stanford, CA, USA

Lung Cancer Screening

Dr Wishart David

University of Alberta, Edmonton, Alberta, Canada

Liquid Biopsy in Cancer Screening: The Contribution of Metabolomics

Dr Aadel Chaudhuri

Washington University School of Medicine, St. Louis, USA

The evolving role of MRD in Solid Tumors

Dr Maria Jose Serrano

Centro Pfizer – Universidad de Granada – Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Spain

Cancer interception beyond ctDNA

Dr Chris Abbosh

The Francis Crick Institute - Cancer Research UK - University College London Cancer Institute, UK

ctDNA Biomarker of Relapse After Resection in Early NSCLC

David Spetzler, MS, PhD, MBA

Caris Life Sciences - President and Chief Scientific Officer, AZ, USA

Transforming Liquid Biopsy: Advancing Clinical Utility for Physicians and Patients

Dr Amy Moore

VP, Global Engagement and Patients Partnership LUNGevity, USA

Role of the advocacy in Liquid Biopsy

RN, ONC, Allison Gittens

Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, USA

Molecular Nursing:  a new approach for testing increasing and Liquid Biopsy awareness

Dr Valeria Denninghoff

University of Buenos Aires (UBA) - National Council for Scientific and Technical Research (CONICET), Argentina

Clinical Application in Latin America: Why so complicated?

Dr Ullas Batra

Rajiv Gandhi Cancer Institute, Delhi, India

Clinical Application in India: It’s Universal Use a reality or a mirage?

Dr Ola Khorshid

National Cancer Institute, Cairo, Egypt

Clinical Application in MENA (Middle East and North Africa) Region: Different realities

Dr Cardinale Smith

Center for Thoracic Oncology, Tisch Cancer Institute, Icahn school of Medicine at Mount Sinai, New York, NY, USA

Disparities in Molecular Testing

Dana Connors

ILSA, Foundation for the National Institutes of Health, USA

ILSA community: a partnership for standardization of Liquid Biopsy

TBD

TBD

FDA Initiatives for Liquid Biopsy application and standardization

Dr. Luca Mazzarella, MD, Ph.D

Group Leader and Clinical Scientist at European Institute of Oncology (IEO), Milan, Italy

Limitations to widespread implementation of liquid biopsy